219 related articles for article (PubMed ID: 15308883)
21. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
Ohishi M; Takeya Y; Tatara Y; Yamamoto K; Onishi M; Maekawa Y; Kamide K; Rakugi H
Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
[TBL] [Abstract][Full Text] [Related]
22. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both.
Verdecchia P; Angeli F
Clin Ther; 2004 Apr; 26(4):460-72. PubMed ID: 15189744
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
Lassila M; Davis BJ; Allen TJ; Burrell LM; Cooper ME; Cao Z
Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.
Savoia C; Touyz RM; Volpe M; Schiffrin EL
Hypertension; 2007 Feb; 49(2):341-6. PubMed ID: 17159079
[TBL] [Abstract][Full Text] [Related]
27. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
28. Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation.
Julius S
Cardiology; 1999; 91 Suppl 1():8-13. PubMed ID: 10449889
[TBL] [Abstract][Full Text] [Related]
29. Overview of clinical use and side effect profile of valsartan in Chinese hypertensive patients.
Huang QF; Li Y; Wang JG
Drug Des Devel Ther; 2013 Dec; 8():79-86. PubMed ID: 24403822
[TBL] [Abstract][Full Text] [Related]
30. Aliskiren/valsartan (Valturna) for hypertension.
Med Lett Drugs Ther; 2009 Nov; 51(1326):94-5. PubMed ID: 20224524
[No Abstract] [Full Text] [Related]
31. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
Frampton JE; Scott LJ
Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840
[TBL] [Abstract][Full Text] [Related]
32. Valsartan plus hydrochlorothiazide: a review of its use since its introduction.
Bains J; Smith WB
Expert Opin Pharmacother; 2011 Aug; 12(12):1975-84. PubMed ID: 21728903
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial.
Everett BM; Glynn RJ; Danielson E; Ridker PM;
Clin Ther; 2008 Apr; 30(4):661-72. PubMed ID: 18498915
[TBL] [Abstract][Full Text] [Related]
34. Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension.
Sander GE; Giles TD
Expert Opin Pharmacother; 2015 Apr; 16(5):763-70. PubMed ID: 25747524
[TBL] [Abstract][Full Text] [Related]
35. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
[TBL] [Abstract][Full Text] [Related]
36. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
37. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
Thomas GN; Chan P; Tomlinson B
Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
[TBL] [Abstract][Full Text] [Related]
38. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study.
Mochizuki S; Dahlöf B; Shimizu M; Ikewaki K; Yoshikawa M; Taniguchi I; Ohta M; Yamada T; Ogawa K; Kanae K; Kawai M; Seki S; Okazaki F; Taniguchi M; Yoshida S; Tajima N;
Lancet; 2007 Apr; 369(9571):1431-1439. PubMed ID: 17467513
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin II antagonism in clinical practice: experience with valsartan.
McInnes GT
J Cardiovasc Pharmacol; 1999; 33 Suppl 1():S29-32; discussion S41-3. PubMed ID: 10028951
[TBL] [Abstract][Full Text] [Related]
40. Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.
Meredith PA
Curr Med Res Opin; 2007 Jul; 23(7):1693-705. PubMed ID: 17588300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
